Vesalius connects licensed prescribers with participating pharmacies for patient-specific peptide prescriptions, manufactured in the United States.
Vesalius closes the gap between longevity science and clinical practice in one platform.
Vesalius connects providers and pharmacies. The licensed prescriber and the participating pharmacy fit together like two pieces of one puzzle, and Vesalius keeps the quality documentation that joins them. Peptide products are manufactured in the United States in accordance with the highest standards and all applicable legislation.
Vesalius peptides are manufactured in the United States and dispensed through participating pharmacies.
There are steps between a bulk manufacturer and a patient receiving medication, and each one leaves a record. Turn the wheel to follow a lot from where it is made, through testing and documentation, to the participating pharmacy that dispenses it.
Our bulk substance is manufactured in a 510(a) FDA-registered lab under Current Good Manufacturing Practice (cGMP).
Substance identity and purity certified.
Each lot’s test results are recorded in a certificate of analysis. A certificate documents the results of testing for a specific lot.
Patient-specific prescription from a licensed prescriber required.
Contact Vesalius with questions about current products and participating pharmacies.
Ask about provider eligibility, participating pharmacies, current products and the process for submitting a prescription.
Request Provider Information
Contact Vesalius about your account, current product availability or the process.
Ask About Your AccountVesalius Longevity Labs Inc. (CSE: SE) (to trade as “VLAB”) will commence trading on the Canadian Securities Exchange under the symbol “VLAB” on November 12, 2026, further to its Listing Statement dated November 9, 2026.
Vesalius Longevity Labs Inc. (CSE: SE, to trade as “VLAB”) has completed a non-brokered private placement of 6,190,475 units at US$1.05 per Unit, for aggregate gross proceeds of US$6,499,998.75, led by an investor group organized by Harvey Spevak, Chairman of Equinox Group.
Celularity will serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, establishing a United States final-stage API manufacturing and supply platform.
Vesalius Longevity Labs Inc. has closed its previously announced business combination with Vesalius Longevity Labs (Canada) Inc. and Vesalius Longevity Labs (SPV) Inc.
Disclaimer: The information provided on this website is intended for general educational and informational purposes only. Vesalius Longevity Labs provides information relating to peptide science, longevity, wellness, metabolic health, and emerging areas of medical research.
FDA Approval & Investigational Therapies: Not all peptides, compounds, medications, or therapies discussed or referenced on this website are approved by the U.S. Food and Drug Administration (FDA). Certain compounds may be investigational, have limited clinical evidence, or lack established long-term safety and efficacy data. References to scientific research, emerging therapies, or potential health benefits are provided for informational purposes and should not be interpreted as claims of FDA approval, established clinical effectiveness, or guaranteed therapeutic outcomes. Where legally permitted, certain medications may be compounded by appropriately licensed pharmacies in accordance with applicable federal and state laws. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing in the same manner as FDA-approved medications. Read the full disclaimer.
